C Ferrándiz1, J M Carrascosa2, M Toro2. 1. Servicio de Dermatología, Hospital Universitario Germans Trias i Pujol, Universitat Autónoma de Barcelona, Badalona, Barcelona, España. Electronic address: cferrandiz.germanstrias@gencat.cat. 2. Servicio de Dermatología, Hospital Universitario Germans Trias i Pujol, Universitat Autónoma de Barcelona, Badalona, Barcelona, España.
Abstract
INTRODUCTION: The prevalence of psoriasis in Spain was estimated to be 1.4% before the advent of biologic agents. Fifteen years later, new therapeutic options based on biologic agents have led to greater awareness of the disease and better understanding; case detection and diagnosis may have improved as a result. OBJECTIVE: To investigate the current prevalence of psoriasis in Spain and compare the results with those of an earlier study that used the same methodology. MATERIAL AND METHODS: Population-based cross-sectional survey. Information was collected through computer-assisted telephone interviews with a randomly selected representative sample of the Spanish population (12,711 individuals from 4,754 households). Interviews were conducted by trained personnel using a questionnaire. RESULTS: The prevalence was 2.3% and there were no statistically significant differences between the sexes. Prevalence increased with age (range with highest prevalence, 60-69 years). Central Spain-a region with a cold, dry climate-had the highest prevalence, but differences between regions were not significant. CONCLUSIONS: Psoriasis is substantially more prevalent in Spain than was previously estimated. The increase in prevalence may reflect greater awareness and better diagnosis of the disease rather than a true increase in number of cases.
INTRODUCTION: The prevalence of psoriasis in Spain was estimated to be 1.4% before the advent of biologic agents. Fifteen years later, new therapeutic options based on biologic agents have led to greater awareness of the disease and better understanding; case detection and diagnosis may have improved as a result. OBJECTIVE: To investigate the current prevalence of psoriasis in Spain and compare the results with those of an earlier study that used the same methodology. MATERIAL AND METHODS: Population-based cross-sectional survey. Information was collected through computer-assisted telephone interviews with a randomly selected representative sample of the Spanish population (12,711 individuals from 4,754 households). Interviews were conducted by trained personnel using a questionnaire. RESULTS: The prevalence was 2.3% and there were no statistically significant differences between the sexes. Prevalence increased with age (range with highest prevalence, 60-69 years). Central Spain-a region with a cold, dry climate-had the highest prevalence, but differences between regions were not significant. CONCLUSIONS:Psoriasis is substantially more prevalent in Spain than was previously estimated. The increase in prevalence may reflect greater awareness and better diagnosis of the disease rather than a true increase in number of cases.
Authors: P C M van de Kerkhof; K Reich; A Kavanaugh; H Bachelez; J Barker; G Girolomoni; R G Langley; C F Paul; L Puig; M G Lebwohl Journal: J Eur Acad Dermatol Venereol Date: 2015-04-16 Impact factor: 6.166
Authors: Néboa Zozaya; Lucía Martínez-Galdeano; Bleric Alcalá; Jose Carlos Armario-Hita; Concepción Carmona; Jose Manuel Carrascosa; Pedro Herranz; María Jesús Lamas; Marta Trapero-Bertran; Álvaro Hidalgo-Vega Journal: BioDrugs Date: 2018-06 Impact factor: 5.807
Authors: Antonio Romero Pérez; Rubén Queiro; Daniel Seoane-Mato; Eduard Graell; Eugenio Chamizo; Lara Chaves Chaparro; Sara Rojas Herrera; Jordi Pons Dolset; Miguel A Polo Ostáriz; Susana Ruiz-Alejos Garrido; Cristina Macía-Villa; Ana Cruz-Valenciano; María L González Gómez; Carlos Sánchez-Piedra; Federico Díaz-González; Sagrario Bustabad-Reyes Journal: PLoS One Date: 2020-06-17 Impact factor: 3.240
Authors: Francisco Javier Martinez-Orozco; Jose Luis Vicario; Clara De Andres; Miguel Fernandez-Arquero; Rosa Peraita-Adrados Journal: J Clin Med Res Date: 2016-05-29
Authors: D A Springate; R Parisi; E Kontopantelis; D Reeves; C E M Griffiths; D M Ashcroft Journal: Br J Dermatol Date: 2016-12-22 Impact factor: 9.302